The prevention of any malignancy inevitably depends on the successful interruption of the transition from a precursor to a malignant state. To accomplish this, the precursor must be known. The precursor to pelvic serous carcinoma has not been previously identified, hampering efforts to study its evolution from benign mucosa. This application summarizes a series of studies that will explore the relationship between a clonal, epithelial-specific alteration in p53 function (""""""""p53 signature"""""""") in the distal fallopian tube and pelvic serous carcinoma. This plan of study is justified by the recent discoveries that 1) the distal fallopian tube is the principal site of early serous carcinoma development in women with germ line BRCA mutations (BRCA+), 2) it is a possible site of origin for over one half of """"""""ovarian"""""""" serous carcinomas, and 3) harbors this candidate precursor. The proposed studies are designed to clarify the link between p53 signatures and pelvic serous carcinoma by attempting to connect them topographically and genetically to early serous carcinomas, identifying biomarkers that are shared between p53 signatures and early serous carcinoma, and establishing an in vitro model from cultures of secretory mucosal cells. These pilot studies are designed to establish the p53 signature as a necessary if not sufficient event in the pathogenesis of pelvic serous carcinoma. If successful, these studies will be followed by more focused applications designed to prospectively test the p53 signature as a surrogate endpoint for serous carcinoma, that if ameliorated, will alter the risk of this lethal form of epithelial ovarian cancer. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA124688-02
Application #
7498471
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Kim, Kelly Y
Project Start
2007-09-20
Project End
2010-08-31
Budget Start
2008-09-01
Budget End
2010-08-31
Support Year
2
Fiscal Year
2008
Total Cost
$143,004
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Sherman, Mark E; Drapkin, Ronny I; Horowitz, Neil S et al. (2016) Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. Cancer Prev Res (Phila) 9:713-20
Conner, James R; Meserve, Emily; Pizer, Ellen et al. (2014) Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol 132:280-6
Ning, Gang; Bijron, Jonathan G; Yamamoto, Yusuke et al. (2014) The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium. J Pathol 234:478-87
Herfs, Michael; Parra-Herran, Carlos; Howitt, Brooke E et al. (2013) Cervical squamocolumnar junction-specific markers define distinct, clinically relevant subsets of low-grade squamous intraepithelial lesions. Am J Surg Pathol 37:1311-8
Merritt, Melissa A; Bentink, Stefan; Schwede, Matthew et al. (2013) Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes. PLoS One 8:e80314
Crum, Christopher P; McKeon, Frank D; Xian, Wa (2012) The oviduct and ovarian cancer: causality, clinical implications, and ""targeted prevention"". Clin Obstet Gynecol 55:24-35
Xian, Wa; Ho, Khek Yu; Crum, Christopher P et al. (2012) Cellular origin of Barrett's esophagus: controversy and therapeutic implications. Gastroenterology 142:1424-30
Xian, Wa; McKeon, Frank (2012) Adult stem cells underlying lung regeneration. Cell Cycle 11:887-94
Herfs, Michael; Yamamoto, Yusuke; Laury, Anna et al. (2012) A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 109:10516-21
Mehra, Karishma K; Chang, Martin C; Folkins, Ann K et al. (2011) The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls. Mod Pathol 24:152-6

Showing the most recent 10 out of 34 publications